Eleven Biotherapeutics Establishes Scientific Advisory Board To Guide Ophthalmic Pipeline And Technology Development
12/27/2013 8:31:15 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today that it has established a Scientific Advisory Board (SAB) to guide the Company’s core therapeutic and technologic approaches, including its ophthalmic pipeline and protein engineering platform. The members of the SAB include clinical and scientific experts in the areas of ocular disease (both front and back of the eye), immunology and cytokine biology and protein engineering. Listed in alphabetical order, the members are: Peter Campochiaro, MD, Johns Hopkins School of Medicine, Wilmer Eye Institute; Reza Dana, MD, Harvard Medical School, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary; Patricia D’Amore, MD, Harvard Medical School, Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary; K. Christopher Garcia, PhD, Stanford University, Howard Hughes Medical Institute; Casey Weaver, MD, University of Alabama School of Medicine.
Help employers find you! Check out all the jobs and post your resume.
comments powered by